FIELD: chemistry.
SUBSTANCE: invention relates to a compound of Formula I which can find application for treating prostate or pancreatic cancer. In formula IL is in meta- or para - position of phenyl ring; L means (CH2)1-2 and R1 is selected from the group consisting of nitrogen-containing 5–7 membered heterocycloalkyl, which may contain a second heteroatom, and NR9R10; or L denotes (CH2)1-5NH and R1 is C5-7cycloalkyl; wherein nitrogen-containing 5–7 membered heterocycloalkyl is optionally substituted with C1-C6 alkyl; R2 is C2-4 straight chain alkanediyl; R3 denotes H; R4 is C2-4straight chain alkanediyl; R9 and R10 are independently C1-6 alkyl; and X is NR62, where the R6groups together with the N atom to which they are attached form pyrrolidin-1-yl. Invention also relates to a pharmaceutical composition containing said compound and a method for production thereof.
EFFECT: substituted naphthalene diimides and their use are disclosed.
10 cl, 1 dwg, 4 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FGFR AND ITS MUTATION INHIBITOR, METHOD OF ITS PREPARATION AND USE | 2021 |
|
RU2811207C1 |
| PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | 2014 |
|
RU2677653C2 |
| METHOD FOR PREDICTING THE THERAPEUTIC EFFECT OF AN LSD 1INHIBITOR BASED ON THE INSM1 EXPRESSION | 2018 |
|
RU2789449C2 |
| AVB6 INTEGRIN INHIBITORS | 2018 |
|
RU2769702C2 |
| NOVEL COMPOUNDS OF SUBSTITUTED N-(3-FLUOROPROPYL)PYRROLIDINE, METHODS FOR PRODUCTION THEREOF AND THERAPEUTIC APPLICATION THEREOF | 2017 |
|
RU2742278C2 |
| PYRAZINE DERIVATIVES USED AS ATR KINASE INHIBITORS | 2009 |
|
RU2604066C2 |
| NEW BIPHENYL COMPOUND OR ITS SALT | 2016 |
|
RU2726622C2 |
| DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS SUITABLE AS KINASE INHIBITORS FOR TREATMENT OF PROLIFERATIVE DISEASES | 2012 |
|
RU2664055C2 |
| COMPOUNDS FOR INHIBITING KINASE EGFR, METHODS FOR PRODUCTION AND USE THEREOF | 2020 |
|
RU2832925C2 |
| HER2 MUTATION INHIBITORS | 2022 |
|
RU2834124C2 |
